A Clinical Trial of Infliximab for Uveitis
This project is designed to test the hypothesis that inhibition of binding between tumor necrosis factor alpha (TNF-alpha) and its receptors using Remicade (infliximab, chimeric mouse/human IgG1K monoclonal antibody directed against human TNF-alpha, Centocor, Malvern,PA) is clinically useful for patients with uveitis that is refractory to other forms of systemic immunosuppressive therapy.
|Official Title:||The Use of Remicade (Infliximab) in the Management of Vision-threatening Uveitis That is Refractory to Other Modes of Systemic Immunosuppression|
|Principal Investigator:||James T Rosenbaum, MD||Oregon Health and Science University|
|Study Director:||Eric B Suhler, MD||Oregon Health and Science University|
|Study Director:||Justine Smith, MBBS, Phd||Oregon Health and Science University|